Managing Gastrointestinal Toxicities from Immune Checkpoint Inhibitors in Cancer Patients
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but cause gastrointestinal (GI) side effects in up to 40% of patients, including inflammatory conditions of the colon, liver, stomach, pancreas, and gallbladder. These GI adverse events are among the most common severe (grade 3+) complications from ICIs. Dr. Saurin Chokshi emphasizes the importance of setting expectations and educating patients about these potential side effects before starting immunotherapy.
Key quotes
GI adverse events, including inflammatory conditions of the colon, liver, stomach, pancreas, and gallbladder, affect up to 40% of patients on ICIs.
This underlies the importance of setting expectations and educating the patient.
They're also among the most common grade 3 or higher adverse events experienced with the drugs.
From the article
You might also wanna read
Infliximab for Immune Checkpoint Inhibitor Associated AKI
Biohacker Bryan Johnson Diagnosed with Incurable Autoimmune Gastritis
Bryan Johnson, the tech entrepreneur and longevity advocate known for his extreme $2 million/year health regimen, has been diagnosed with au
impactnews-wire.com·20h agoAdaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Soluble Immune Checkpoints in Intra-Abdominal Infections
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Gut microbiome composition predicts melanoma recurrence risk in patients on immunotherapy, large trial finds
This study analyzed stool samples from 674 patients with resected high-risk melanoma enrolled in the phase 3 CheckMate 915 clinical trial to
Comments
Sign in to join the conversation.
No comments yet. Be the first.